# OnCo record krascendo-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/krascendo-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "krascendo-1", "NCT06497556" ;
  schema:name "Krascendo 1"@en ;
  schema:description "The first head-to-head trial among KRAS drugs: Roche's divarasib beat the two approved pills on progression and survival."@en ;
  schema:url <https://onco.cc/trials/krascendo-1/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06497556>, <https://www.roche.com/media/releases/med-cor-2026-07-02> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2024-09-23" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> .